Amyloid and tau PET is considered to be a sensitive and specific neuroimaging biomarker for AD, with recent criteria proposing that amyloid- and tau-positive PET suffice for an AD diagnosis [128,129]. The gene discussed is MAPT; the disease is Alzheimer disease.